CD20-targeted CAR-T cells for blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of CAR-T therapy (a treatment that uses your own immune cells, genetically changed to attack cancer) that targets a protein called CD20 found on some blood cancer cells. It's for people with B-cell lymphoma or lymphocytic leukemia who have already had other treatments and need a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You have a type of blood cancer called CD20-positive B-cell lymphoma or lymphocytic leukemia, and you've already had some standard treatment.
- You are generally feeling well enough to do daily activities (ECOG score 0 or 1).
- If you have lymphoma, you need to have at least one tumor that can be measured by scans or exams.
- You must use reliable birth control during the study and for 30 days after the last treatment.
- You cannot have certain infections (like HIV, hepatitis B or C) or serious heart or blood vessel problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This study tests a new type of immune therapy called CAR-T cells, which are made from your own blood cells to find and attack cancer. It is for adults with leukemia or lymphoma that has come back or is hard to treat.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This study tests a new type of CAR T cell therapy that targets the CD20 protein on B-cell lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded to at least two previous treatments and who cannot use or have already tried the approved CD19 CAR T therapy.
This trial tests a new type of immune cell therapy called CAR-T cells that are designed to find and destroy cancer cells with the CD19 or CD22 markers. The goal is to see if this experimental treatment can help people with B-cell acute lymphoblastic leukemia or non-Hodgkin's lymphoma when other treatments haven't worked.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.